BioSpace News Archive

Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM (carcinoembryonic antigen-related cell adhesion molecules) antibodies as anti-cancer treatments, today announced that it has signed a collaboration agreement with YUMAB GmbH, a privately-held German biotechnology company.

Fauna Bio, a biotechnology company pioneering the fields of comparative, computational and translational genomics, is celebrating its fourth birthday this month with the release of Centaur, a knowledge graph that is the first of its kind to visualize the intersection between animal gene expression data and human diseases in one comprehensive map.

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation detailing initial Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study (NCT04939610) investigating the safety, pharmacokinetics, dosimetry, and preliminary antitumor activity of its targeted radiotherapy candidate, FAP-2286 labelled with lutetium-177 (177Lu-FAP-2286).

CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company’s Amended and Restated 2017 Equity Incentive Plan and material to the employee’s acceptance of employment with the company.

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced receipt of a written response from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and from the U.S. Food and Drug Administration (FDA) related to questions submitted in a Type C meeting request on the Company’s planned use of anti-TNF treatment, adalimumab, to treat early-stage Dupuytren’s disease.

VectivBio Holding AG, a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced the launch of a follow-on public offering of its ordinary shares.

Abiomed, Inc. (NASDAQ: ABMD) today announced that it will host an investor call on the heart failure opportunity with the Impella 5.5 and future Impella BTR heart pumps on June 24, 2022 from 2:30 p.m. – 3:30 p.m. ET.

Travere Therapeutics, Inc. announced that on June 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants to ten new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 48,750 shares of its common stock.

BIOASIS TECHNOLOGIES INC. announced it has filed its audited annual financial statements and management’s discussion and analysis for the period ended February 28, 2022.

The global infusion pump market size is expected to reach USD 28.01 Billion in 2030 and register a revenue CAGR of 9.4% over the forecast period, according to latest report by Reports and Data.